glp 1 gip triple agonist retatrutide mechanism glp-1 glucagon Treatment with retatrutide, an agonist to GLP-1 Targeting GLP-1, GIP & GCG

Statements Data availability statement The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author

Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study

In both patient populations with pre-existing cardiovascular disease, DPP-4 inhibitors are recommended as one possible third-line therapy besides SGLT-2 inhibitors, thiazolidinediones, or insulin, when therapeutic goals are not met with the previous dual combination

Ann Family Med 10(1):1522 Rubin RR (2005) Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus

Our market revenue calculations use a bottom-up methodology that accounts for all players across all regions - including manufacturers, distributors, and specialists not individually profiled

A., & Gooley, J